Dupilumab in Adults with Moderate-to-Severe Atopic Dermatitis and Prior Use of Systemic Non-Steroidal Immunosuppressants: Analysis of Four Phase 3 Trials

INTRODUCTION: Dupilumab is approved as first-line systemic treatment for adults/adolescents with moderate-to-severe atopic dermatitis (AD) in Europe and elsewhere owing to its favourable benefit–risk profile. However, systemic non-steroidal immunosuppressants (NSISS) are often used as first-line the...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Dermatol Ther (Heidelb)
Autors principals: Griffiths, Christopher, de Bruin-Weller, Marjolein, Deleuran, Mette, Fargnoli, Maria Concetta, Staumont-Sallé, Delphine, Hong, Chih-ho, Sánchez-Carazo, Jose, Foley, Peter, Seo, Seong Jun, Msihid, Jérôme, Chen, Zhen, Cyr, Sonya L., Rossi, Ana B.
Format: Artigo
Idioma:Inglês
Publicat: Springer Healthcare 2021
Matèries:
Original Research
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC8322347/
https://ncbi.nlm.nih.gov/pubmed/34142350
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13555-021-00558-0
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars